CD8A and lymphoma: Specific immunotherapy strategies, such as EBV-specific CD8+ cytotoxic T-cell adoptive therapy, have shown success in nasopharyngeal carcinoma and lymphoma and may further optimize EBVaGC treatment by targeting EBV antigens in the future.